Premium
THE EFFECT OF CLOMIPHENE ON UNCASTRATED AND CASTRATED MALE TRANSSEXUALS
Author(s) -
GOH H. H.,
CHEW P. C. T.,
KARIM S. M. M.,
RATNAM S. S.
Publication year - 1979
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1979.tb03072.x
Subject(s) - medicine , endocrinology , testosterone (patch) , basal (medicine) , luteinizing hormone , follicle stimulating hormone , biology , hormone , insulin
SUMMARY Clomiphene was administered at a daily dose of 100 mg for 5 consecutive days to two groups of male subjects. There were three uncastrated male transsexuals (Group A) and nine castrated male transsexuals (Group B). In the uncastrated subjects Clomiphene enhanced the secretion of follicle‐stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (T) starting from day 3 of treatment. The magnitude of the increment ranged from 150%–250% over the mean basal plasma level for LH, 113%–262% for FSH and 12%–68% for T. In contrast, Clomiphene suppressed both FSH and LH in the castrated subjects. Equal suppression of both the gonadotrophins were observed. The levels of FSH and LH in plasma on day 3 were suppressed to 66.4% and 66.2% of their respective mean basal levels. Two days after the termination of treatment, suppressions were maintained. These results suggest that Clomiphene acts as an anti‐oestrogen in uncastrated male transsexuals and in castrated male transsexuals who have subphysiological levels of oestradiol it acts as a weak oestrogen.